Thermo Fisher Scientific Inc. $TMO Shares Bought by James Hambro & Partners LLP

Key Points

• James Hambro & Partners LLP increased its stake in Thermo Fisher Scientific Inc. by 9.8%, holding 257,327 shares valued at approximately $104.3 million as of its latest filing.
• Several other hedge funds also raised their positions in Thermo Fisher during the second quarter, with institutional investors and hedge funds owning 89.23% of the company's stock.
• Thermo Fisher reported $5.36 earnings per share for the last quarter, surpassing analyst expectations, and guided for Q3 2025 EPS between 5.460-5.510.

James Hambro & Partners LLP raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 257,327 shares of the medical research company's stock after buying an additional 22,904 shares during the quarter. Thermo Fisher Scientific comprises about 4.1% of James Hambro & Partners LLP's portfolio, making the stock its 14th biggest holding. James Hambro & Partners LLP owned about 0.07% of Thermo Fisher Scientific worth $104,296,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also made changes to their positions in the business. Avior Wealth Management LLC increased its stake in shares of Thermo Fisher Scientific by 24.5% during the second quarter. Avior Wealth Management LLC now owns 4,096 shares of the medical research company's stock worth $1,661,000 after buying an additional 806 shares during the period. Charles Schwab Trust Co boosted its holdings in shares of Thermo Fisher Scientific by 50.2% in the second quarter. Charles Schwab Trust Co now owns 673 shares of the medical research company's stock valued at $273,000 after acquiring an additional 225 shares during the period. Spirepoint Private Client LLC boosted its holdings in shares of Thermo Fisher Scientific by 2.4% in the second quarter. Spirepoint Private Client LLC now owns 11,483 shares of the medical research company's stock valued at $4,656,000 after acquiring an additional 272 shares during the period. Processus Wealth & Capital Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 2.9% during the second quarter. Processus Wealth & Capital Management LLC now owns 6,287 shares of the medical research company's stock worth $2,549,000 after purchasing an additional 180 shares during the period. Finally, ORG Wealth Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 12.5% during the second quarter. ORG Wealth Partners LLC now owns 1,101 shares of the medical research company's stock worth $464,000 after purchasing an additional 122 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the sale, the chief executive officer owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

TMO has been the subject of a number of recent analyst reports. Wells Fargo & Company reduced their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a report on Thursday, July 24th. Raymond James Financial restated an "outperform" rating and issued a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. UBS Group raised their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a research report on Friday, July 11th. Finally, Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an "outperform" rating in a research note on Tuesday, September 2nd. Sixteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $588.35.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $464.18 on Friday. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $623.77. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $175.28 billion, a price-to-earnings ratio of 26.85, a price-to-earnings-growth ratio of 2.52 and a beta of 0.75. The business has a 50 day simple moving average of $476.70 and a 200-day simple moving average of $447.57.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business's quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the business earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.